MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Core Insights - MIRA Pharmaceuticals, Inc. has initiated the multiple ascending dose (MAD) portion of its Phase 1 clinical trial for its lead oral candidate, Ketamir-2, targeting chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for Phase 2a evaluation [1] Company Developments - The company is focused on developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders [1] - The Phase 1 clinical trial is currently evaluating Ketamir-2 in healthy volunteers [1] - CIPN is identified as a common and debilitating side effect of cancer treatment, highlighting the potential market need for effective therapies [1]